A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Citalopram; Dexetimide; Methylphenidate; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• Adult patients, 18 to 45 years of age

• In good general health

• Weight of ≥120 lbs (55 kg) and a body mass index (BMI) between 18 to 30kg/m²

• Males and females with reproductive potential: willing to use a reliable method of contraception

Exclusion Criteria:

• Evidence of clinically significant disease

• Medical or surgical condition that could alter the absorption, metabolism, or elimination of drugs

• Family history of sudden death or ventricular arrhythmia

• History of any psychiatric disorder and/or marked anxiety

• History of glaucoma

• History (including family) of motor tic or diagnosis of Tourette's syndrome

• Active suicide ideation

• Contraindication to MRI